Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.65 |
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.57 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dynorphin B SCHEMBL29374545 | 0.91 | OPRD1 (0.61) | TFPIOPRM1OPRD1OPRK1 | |
| Dynorphin B SCHEMBL30589448 | 0.91 | OPRD1 (0.61) | TFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL30385132 | 0.90 | TFPI (0.63) | TFPIIL23RKEAP1OPRM1OPRD1 | |
| SCHEMBL29770069 | 0.89 | TFPI (0.63) | TFPIIL23RKEAP1OPRM1OPRD1 | |
| SCHEMBL31683364 | 0.88 | TFPI (0.67) | TFPIKEAP1VIPR2VIPR1 | |
| SCHEMBL29834951 | 0.88 | TFPI (0.62) | TFPIIL23RKEAP1OPRM1OPRD1 | |
| SCHEMBL29834939 | 0.88 | TFPI (0.62) | TFPIIL23RKEAP1OPRM1OPRD1 | |
| SCHEMBL30184205 | 0.88 | OPRM1 (0.61) | TFPIIL23RKEAP1OPRM1OPRD1 | |
| SCHEMBL29430569 | 0.87 | TFPI (0.70) | TFPIIL23RVIPR2VIPR1 | |
| SCHEMBL31243890 | 0.87 | OPRM1 (0.57) | TFPIIL23RKEAP1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | BIOHAVEN THERAPEUTICS LTD. (VG) | 2026-03-03 | — | — | US | disclosed |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | BIOHAVEN THERAPEUTICS LTD (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4168116-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | Biohaven Therapeutics Ltd. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | CERS2, CNR2, FAAH2 | TFPI 2357/4885IL23R 409/4885KEAP1 1178/4885 |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | TRPV1, PNN, SLC18A2 | TFPI 4455/4885IL23R 1566/4885KEAP1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.